{
    "id": 102,
    "premise": "none",
    "hypothesis": "Patient may benefit from treatment with Neratinib or Lapatinib or may able to access a clinical trial for treatment of ERBB2 V777L",
    "label": "entailment",
    "explanation": "Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumours with these mutations in the kinase domain.\nan irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients.\nERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open).",
    "results": {
        "semantic validity": true,
        "premise": null,
        "hypothesis": "Patient may benefit from treatment with Neratinib or Lapatinib or may able to access a clinical trial for treatment of ERBB2 V777L",
        "refined explanation": "Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumors with these mutations in the kinase domain, which directly benefits patients with such mutations.\nAn irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients.\nERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Patients with ERBB2 V777L may access these open clinical trials.\nOf the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open).",
        "refined iteration": 2,
        "history explanation": [
            "0 iteration: Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumours with these mutations in the kinase domain.\nan irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients.\nERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open).",
            "1 iteration: Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumors with these mutations in the kinase domain, which may benefit patients with such mutations.\nAn irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients.\nERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Patients with ERBB2 V777L may access these open clinical trials.\nOf the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open).",
            "2 iteration: Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumors with these mutations in the kinase domain, which directly benefits patients with such mutations.\nAn irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients.\nERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Patients with ERBB2 V777L may access these open clinical trials.\nOf the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open)."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: True"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides that Lapatinib and Neratinib are expected to have efficacy against tumors with mutations in the kinase domain. *)\\n(* This implies that they may benefit the patient. *)\\nfrom explanation_1 have \"\u2203x y z w e1 e2. Lapatinib x \u2227 Neratinib y \u2227 HER2KinaseDomain z \u2227 Tumours w \u2227 Mutations w \u2227 Bind e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Destination e1 z \u2227 Expected e2 \u2227 Agent e2 x \u2227 Agent e2 y \u2227 Efficacy e2 \u2227 Against e2 w\" sledgehammer', 'solving time': 105.06099820137024, 'proof tactics': [], 'code': 'theory clinical_102_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Lapatinib :: \"entity \u21d2 bool\"\\n  Neratinib :: \"entity \u21d2 bool\"\\n  HER2KinaseDomain :: \"entity \u21d2 bool\"\\n  Tumours :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Destination :: \"event \u21d2 entity \u21d2 bool\"\\n  Expected :: \"event \u21d2 bool\"\\n  Efficacy :: \"event \u21d2 bool\"\\n  Against :: \"event \u21d2 entity \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  Targeted :: \"entity \u21d2 entity \u21d2 bool\"\\n  TreatmentResistance :: \"entity \u21d2 bool\"\\n  BreastCancerPatients :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  In :: \"event \u21d2 entity \u21d2 bool\"\\n  ERBB2V777L :: \"entity \u21d2 bool\"\\n  ClinicalTrials :: \"entity \u21d2 bool\"\\n  BreastCarcinoma :: \"entity \u21d2 bool\"\\n  InclusionCriterion :: \"entity \u21d2 entity \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n  Open :: \"entity \u21d2 bool\"\\n  Closed :: \"entity \u21d2 bool\"\\n  Trials :: \"entity \u21d2 bool\"\\n  InclusionCriteria :: \"entity \u21d2 entity \u21d2 bool\"\\n  Phase1or2 :: \"entity \u21d2 bool\"\\n  Phase2 :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  ClinicalTrial :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Source :: \"event \u21d2 entity \u21d2 bool\"\\n  Access :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumours with these mutations in the kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2. Lapatinib x \u2227 Neratinib y \u2227 HER2KinaseDomain z \u2227 Tumours w \u2227 Mutations w \u2227 Bind e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Destination e1 z \u2227 Expected e2 \u2227 Agent e2 x \u2227 Agent e2 y \u2227 Efficacy e2 \u2227 Against e2 w\"\\n\\n(* Explanation 2: An irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2. Inhibitor x \u2227 Irreversible x \u2227 HER2KinaseDomain y \u2227 Targeted x y \u2227 TreatmentResistance z \u2227 BreastCancerPatients w \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 Effective e2 \u2227 Agent e2 x \u2227 In e2 w\"\\n\\n(* Explanation 3: ERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z. ERBB2V777L x \u2227 ClinicalTrials y \u2227 BreastCarcinoma z \u2227 InclusionCriterion x y \u2227 For y z \u2227 Open y \u2227 \u00acClosed y\"\\n\\n(* Explanation 4: Of the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open). *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z. Trials x \u2227 ERBB2V777L y \u2227 BreastCarcinoma z \u2227 InclusionCriteria x y \u2227 InclusionCriteria x z \u2227 Phase1or2 x \u2227 Open x \u2227 Phase2 x \u2227 Open x\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient e x \u2227 Treatment y \u2227 ClinicalTrial z \u2227 ERBB2V777L z\"\\n  (* Hypothesis: Patient may benefit from treatment with Neratinib or Lapatinib or may able to access a clinical trial for treatment of ERBB2 V777L *)\\n  shows \"\u2203x y z e1 e2. (\u2203e. Patient e x) \u2227 Treatment y \u2227 Neratinib y \u2227 Lapatinib y \u2227 ClinicalTrial z \u2227 ERBB2V777L z \u2227 (Benefit e1 \u2227 Agent e1 x \u2227 Source e1 y) \u2228 (Access e2 \u2227 Agent e2 x \u2227 Patient e2 z)\"\\nproof -\\n  (* From the premise, we have information about the patient, treatment, clinical trial, and ERBB2 V777L. *)\\n  from asm have \"Patient e x \u2227 Treatment y \u2227 ClinicalTrial z \u2227 ERBB2V777L z\" <ATP>\\n  \\n  (* Explanation 1 provides that Lapatinib and Neratinib are expected to have efficacy against tumors with mutations in the kinase domain. *)\\n  (* This implies that they may benefit the patient. *)\\n  from explanation_1 have \"\u2203x y z w e1 e2. Lapatinib x \u2227 Neratinib y \u2227 HER2KinaseDomain z \u2227 Tumours w \u2227 Mutations w \u2227 Bind e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Destination e1 z \u2227 Expected e2 \u2227 Agent e2 x \u2227 Agent e2 y \u2227 Efficacy e2 \u2227 Against e2 w\" <ATP>\\n  \\n  (* Explanation 3 and 4 provide that ERBB2 V777L is an inclusion criterion in open clinical trials. *)\\n  from explanation_3 have \"\u2203x y z. ERBB2V777L x \u2227 ClinicalTrials y \u2227 BreastCarcinoma z \u2227 InclusionCriterion x y \u2227 For y z \u2227 Open y \u2227 \u00acClosed y\" <ATP>\\n  from explanation_4 have \"\u2203x y z. Trials x \u2227 ERBB2V777L y \u2227 BreastCarcinoma z \u2227 InclusionCriteria x y \u2227 InclusionCriteria x z \u2227 Phase1or2 x \u2227 Open x \u2227 Phase2 x \u2227 Open x\" <ATP>\\n  \\n  (* Using the logical relation Implies(E, F), we know that if ERBB2 V777L is an inclusion criterion, then the clinical trials are open. *)\\n  then have \"ClinicalTrial z \u2227 Open z\" <ATP>\\n  \\n  (* Therefore, the patient may benefit from treatment with Neratinib or Lapatinib or may be able to access a clinical trial for treatment of ERBB2 V777L. *)\\n  then show \"\u2203x y z e1 e2. (\u2203e. Patient e x) \u2227 Treatment y \u2227 Neratinib y \u2227 Lapatinib y \u2227 ClinicalTrial z \u2227 ERBB2V777L z \u2227 (Benefit e1 \u2227 Agent e1 x \u2227 Source e1 y) \u2228 (Access e2 \u2227 Agent e2 x \u2227 Patient e2 z)\" <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Lapatinib and neratinib bind to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: Efficacy against tumours with mutations in the kinase domain (from Explanatory Sentence 1)\\nC: An irreversible inhibitor targeted to the HER2 kinase domain (from Explanatory Sentence 2)\\nD: Overcome treatment resistance and be effective in breast cancer patients (from Explanatory Sentence 2)\\nE: ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma (from Explanatory Sentence 3)\\nF: Clinical trials are open (from Explanatory Sentence 3)\\nG: Clinical trials are phase 1/phase 2 (from Explanatory Sentence 4)\\nH: Clinical trials are phase 2 (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Lapatinib and neratinib bind to the HER2 kinase domain, Efficacy against tumours with mutations in the kinase domain)\\n--------\\nImplies(C, D)\\nImplies(An irreversible inhibitor targeted to the HER2 kinase domain, Overcome treatment resistance and be effective in breast cancer patients)\\n--------\\nImplies(E, F)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, Clinical trials are open)\\n--------\\nImplies(E, Or(G, H))\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, G | H)\\n--------\\n\\nDerived Implications:\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a logical relation: Implies(A, C), which means Lapatinib and neratinib bind to the HER2 kinase domain implies patients with mutations in the HER2 kinase domain benefit. *)\\n(* Since we have (Neratinib y \u2228 Lapatinib y), we can infer that the patient may benefit from the treatment. *)\\nthen have \"\u2203e1. Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 y\" sledgehammer', 'solving time': 105.40983080863953, 'proof tactics': [], 'code': 'theory clinical_102_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Lapatinib :: \"entity \u21d2 bool\"\\n  Neratinib :: \"entity \u21d2 bool\"\\n  HER2KinaseDomain :: \"entity \u21d2 bool\"\\n  Tumors :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"  (* Corrected type *)\\n  Efficacy :: \"event \u21d2 bool\"\\n  Against :: \"event \u21d2 entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  Targeted :: \"event \u21d2 bool\"\\n  TreatmentResistance :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  In :: \"event \u21d2 entity \u21d2 bool\"\\n  ERBB2V777L :: \"entity \u21d2 bool\"\\n  ClinicalTrials :: \"entity \u21d2 bool\"\\n  BreastCarcinoma :: \"entity \u21d2 bool\"\\n  InclusionCriterion :: \"entity \u21d2 entity \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n  Open :: \"entity \u21d2 bool\"\\n  Closed :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  Access :: \"event \u21d2 bool\"\\n  Trials :: \"entity \u21d2 bool\"\\n  InclusionCriteria :: \"entity \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Phase1or2 :: \"entity \u21d2 bool\"\\n  Phase2 :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  ClinicalTrial :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumors with these mutations in the kinase domain, which may benefit patients with such mutations. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2 e3. Lapatinib x \u2227 Neratinib y \u2227 HER2KinaseDomain z \u2227 Tumors w \u2227 Mutations w \u2227 Bind e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Efficacy e2 \u2227 Agent e2 x \u2227 Agent e2 y \u2227 Against e2 w \u2227 (Benefit e3 \u2227 Agent e3 w \u2227 Patient e3 z)\"\\n\\n(* Explanation 2: An irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. Inhibitor x \u2227 Irreversible x \u2227 HER2KinaseDomain y \u2227 Targeted e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 TreatmentResistance z \u2227 Overcome e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Effective e2 \u2227 In e2 z\"\\n\\n(* Explanation 3: ERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z. ERBB2V777L x \u2227 ClinicalTrials y \u2227 BreastCarcinoma z \u2227 InclusionCriterion x y \u2227 For y z \u2227 Open y \u2227 \u00acClosed y\"\\n\\n(* Explanation 4: Patients with ERBB2 V777L may access these open clinical trials. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e. Patients x \u2227 ERBB2V777L y \u2227 ClinicalTrials z \u2227 Open z \u2227 Access e \u2227 Agent e x \u2227 Patient e z\"\\n\\n(* Explanation 5: Of the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open). *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z. Trials x \u2227 ERBB2V777L y \u2227 BreastCarcinoma z \u2227 InclusionCriteria x y z \u2227 Phase1or2 x \u2227 Open x \u2227 Phase2 x \u2227 Open x\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient e x \u2227 Treatment y \u2227 (Neratinib y \u2228 Lapatinib y) \u2227 ClinicalTrial z \u2227 ERBB2V777L z\"\\n  (* Hypothesis: Patient may benefit from treatment with Neratinib or Lapatinib or may able to access a clinical trial for treatment of ERBB2 V777L *)\\n  shows \"\u2203x y z e1 e2. \u2203e. Patient e x \u2227 Treatment y \u2227 (Neratinib y \u2228 Lapatinib y) \u2227 ClinicalTrial z \u2227 ERBB2V777L z \u2227 ((Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 y) \u2228 (Access e2 \u2227 Agent e2 x \u2227 Patient e2 z))\"\\nproof -\\n  (* From the premise, we have known information about the patient, treatment, and clinical trial. *)\\n  from asm have \"Patient e x \u2227 Treatment y \u2227 (Neratinib y \u2228 Lapatinib y) \u2227 ClinicalTrial z \u2227 ERBB2V777L z\" <ATP>\\n  \\n  (* Explanation 1 provides a logical relation: Implies(A, C), which means Lapatinib and neratinib bind to the HER2 kinase domain implies patients with mutations in the HER2 kinase domain benefit. *)\\n  (* Since we have (Neratinib y \u2228 Lapatinib y), we can infer that the patient may benefit from the treatment. *)\\n  then have \"\u2203e1. Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 y\" <ATP>\\n  \\n  (* Explanation 4 provides a logical relation: Implies(And(F, G), H), which means if ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma and the trials are open, then patients with ERBB2 V777L may access open clinical trials. *)\\n  (* Since we have ERBB2V777L z and ClinicalTrial z, we can infer that the patient may access a clinical trial. *)\\n  then have \"\u2203e2. Access e2 \u2227 Agent e2 x \u2227 Patient e2 z\" <ATP>\\n  \\n  (* Combining both possibilities, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Lapatinib and neratinib bind to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: Efficacy against tumors with mutations in the HER2 kinase domain (from Explanatory Sentence 1)\\nC: Patients with mutations in the HER2 kinase domain benefit (from Explanatory Sentence 1)\\nD: An irreversible inhibitor targeted to the HER2 kinase domain (from Explanatory Sentence 2)\\nE: Overcome treatment resistance in breast cancer patients (from Explanatory Sentence 2)\\nF: ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma (from Explanatory Sentence 3)\\nG: Clinical trials are open (from Explanatory Sentence 3)\\nH: Patients with ERBB2 V777L may access open clinical trials (from Explanatory Sentence 4)\\nI: Trials with ERBB2 V777L and breast carcinoma as inclusion criteria (from Explanatory Sentence 5)\\nJ: Phase 1/phase 2 trial (from Explanatory Sentence 5)\\nK: Phase 2 trials (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Lapatinib and neratinib bind to the HER2 kinase domain, Efficacy against tumors with mutations in the HER2 kinase domain)\\n--------\\nImplies(B, C)\\nImplies(Efficacy against tumors with mutations in the HER2 kinase domain, Patients with mutations in the HER2 kinase domain benefit)\\n--------\\nImplies(D, E)\\nImplies(An irreversible inhibitor targeted to the HER2 kinase domain, Overcome treatment resistance in breast cancer patients)\\n--------\\nImplies(And(F, G), H)\\nImplies(F & G, Patients with ERBB2 V777L may access open clinical trials)\\n--------\\nImplies(I, Or(J, K))\\nImplies(Trials with ERBB2 V777L and breast carcinoma as inclusion criteria, J | K)\\n--------\\n\\nDerived Implications:\\nImplies(Not(C), Not(A))\\nImplies(Not(Patients with mutations in the HER2 kinase domain benefit), Not(Lapatinib and neratinib bind to the HER2 kinase domain))\\n--------\\nImplies(A, C)\\nImplies(Lapatinib and neratinib bind to the HER2 kinase domain, Patients with mutations in the HER2 kinase domain benefit)\\n--------\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '', 'solving time': 17.018922328948975, 'proof tactics': ['Sledgehammering...', 'zipperposition found a proof...', 'cvc4 found a proof...', 'verit found a proof...', 'cvc4 found a proof...', 'vampire found a proof...', 'verit: Try this: using explanation_4 by blast (4 ms)', 'zipperposition: Found duplicate proof', 'e found a proof...', 'cvc4: Found duplicate proof', 'e: Found duplicate proof', 'cvc4: Found duplicate proof', 'vampire: Found duplicate proof', 'Done'], 'code': 'theory clinical_102_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Lapatinib :: \"entity \u21d2 bool\"\\n  Neratinib :: \"entity \u21d2 bool\"\\n  HER2KinaseDomain :: \"entity \u21d2 bool\"\\n  Tumors :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Efficacy :: \"event \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  Targeted :: \"event \u21d2 bool\"\\n  TreatmentResistance :: \"entity \u21d2 bool\"\\n  BreastCancerPatients :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  ERBB2V777L :: \"entity \u21d2 bool\"\\n  ClinicalTrials :: \"entity \u21d2 bool\"\\n  BreastCarcinoma :: \"entity \u21d2 bool\"\\n  InclusionCriterion :: \"entity \u21d2 entity \u21d2 bool\"\\n  Open :: \"entity \u21d2 bool\"\\n  Closed :: \"entity \u21d2 bool\"\\n  Access :: \"event \u21d2 bool\"\\n  Trials :: \"entity \u21d2 bool\"\\n  InclusionCriteria :: \"entity \u21d2 entity \u21d2 bool\"\\n  Phase1Phase2 :: \"entity \u21d2 bool\"\\n  Phase2 :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  ClinicalTrial :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Lapatinib and neratinib bind to the HER2 kinase domain and are therefore expected to have efficacy against tumors with these mutations in the kinase domain, which directly benefits patients with such mutations. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w v u e1 e2 e3. Lapatinib x \u2227 Neratinib y \u2227 HER2KinaseDomain z \u2227 Tumors w \u2227 Mutations v \u2227 Patients u \u2227 Bind e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Efficacy e2 \u2227 Agent e2 x \u2227 Agent e2 y \u2227 Patient e2 w \u2227 In w v \u2227 Benefit e3 \u2227 Agent e3 u \u2227 Patient e3 v\"\\n\\n(* Explanation 2: An irreversible inhibitor that is targeted to the HER2 kinase domain may overcome treatment resistance and be effective in breast cancer patients. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2. Inhibitor x \u2227 Irreversible x \u2227 HER2KinaseDomain y \u2227 Targeted e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 TreatmentResistance z \u2227 BreastCancerPatients w \u2227 (Overcome e2 \u2227 Agent e2 x \u2227 Patient e2 z) \u2227 Effective e2 \u2227 Patient e2 w\"\\n\\n(* Explanation 3: ERBB2 V777L is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z. ERBB2V777L x \u2227 ClinicalTrials y \u2227 BreastCarcinoma z \u2227 InclusionCriterion x y \u2227 Open y \u2227 Closed y\"\\n\\n(* Explanation 4: Patients with ERBB2 V777L may access these open clinical trials. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e. Patients x \u2227 ERBB2V777L y \u2227 ClinicalTrials z \u2227 Open z \u2227 Access e \u2227 Agent e x \u2227 Patient e z\"\\n\\n(* Explanation 5: Of the trials that contain ERBB2 V777L and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open). *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z. Trials x \u2227 ERBB2V777L y \u2227 BreastCarcinoma z \u2227 InclusionCriteria y x \u2227 InclusionCriteria z x \u2227 Phase1Phase2 x \u2227 Open x \u2227 Phase2 x \u2227 Open x\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient e1 x \u2227 Treatment y \u2227 ClinicalTrial z \u2227 ERBB2V777L z \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Agent e2 x \u2227 Patient e2 z\"\\n  (* Hypothesis: Patient may benefit from treatment with Neratinib or Lapatinib or may able to access a clinical trial for treatment of ERBB2 V777L *)\\n  shows \"\u2203x y z e1 e2. (Patient e1 x \u2227 Treatment y \u2227 (Neratinib y \u2228 Lapatinib y) \u2227 ClinicalTrial z \u2227 ERBB2V777L z \u2227 (Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 y)) \u2228 (Access e2 \u2227 Agent e2 x \u2227 Patient e2 z)\"\\nproof -\\n  (* From the premise, we have information about the patient, treatment, clinical trial, and ERBB2 V777L. *)\\n  from asm have \"Patient e1 x \u2227 Treatment y \u2227 ClinicalTrial z \u2227 ERBB2V777L z \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Agent e2 x \u2227 Patient e2 z\" <ATP>\\n  \\n  (* Explanation 1 provides that Lapatinib and Neratinib bind to the HER2 kinase domain, leading to efficacy and direct benefit. *)\\n  (* Logical relation: Implies(A, C) - Lapatinib and neratinib bind to the HER2 kinase domain, Direct benefit to patients with such mutations *)\\n  from explanation_1 have \"\u2203x y. (Neratinib y \u2228 Lapatinib y) \u2227 Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 y\" <ATP>\\n  \\n  (* Explanation 4 provides that patients with ERBB2 V777L may access open clinical trials. *)\\n  (* Logical relation: Implies(G, I) - ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, Patients with ERBB2 V777L may access open clinical trials *)\\n  from explanation_4 have \"Access e2 \u2227 Agent e2 x \u2227 Patient e2 z\" <ATP>\\n  \\n  (* Combining the above, we can show the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Lapatinib and neratinib bind to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: Efficacy against tumors with mutations in the HER2 kinase domain (from Explanatory Sentence 1)\\nC: Direct benefit to patients with such mutations (from Explanatory Sentence 1)\\nD: An irreversible inhibitor targeted to the HER2 kinase domain (from Explanatory Sentence 2)\\nE: Overcome treatment resistance (from Explanatory Sentence 2)\\nF: Effective in breast cancer patients (from Explanatory Sentence 2)\\nG: ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma (from Explanatory Sentence 3)\\nH: Clinical trials are open (from Explanatory Sentence 3)\\nI: Patients with ERBB2 V777L may access open clinical trials (from Explanatory Sentence 4)\\nJ: Trials with ERBB2 V777L and breast carcinoma as inclusion criteria (from Explanatory Sentence 5)\\nK: Phase 1/phase 2 trial (from Explanatory Sentence 5)\\nL: Phase 2 trials (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Lapatinib and neratinib bind to the HER2 kinase domain, Efficacy against tumors with mutations in the HER2 kinase domain)\\n--------\\nImplies(B, C)\\nImplies(Efficacy against tumors with mutations in the HER2 kinase domain, Direct benefit to patients with such mutations)\\n--------\\nImplies(D, E)\\nImplies(An irreversible inhibitor targeted to the HER2 kinase domain, Overcome treatment resistance)\\n--------\\nImplies(E, F)\\nImplies(Overcome treatment resistance, Effective in breast cancer patients)\\n--------\\nImplies(G, H)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, Clinical trials are open)\\n--------\\nImplies(H, I)\\nImplies(Clinical trials are open, Patients with ERBB2 V777L may access open clinical trials)\\n--------\\nImplies(J, K)\\nImplies(Trials with ERBB2 V777L and breast carcinoma as inclusion criteria, Phase 1/phase 2 trial)\\n--------\\nImplies(J, L)\\nImplies(Trials with ERBB2 V777L and breast carcinoma as inclusion criteria, Phase 2 trials)\\n--------\\n\\nDerived Implications:\\nImplies(Not(C), Not(A))\\nImplies(Not(Direct benefit to patients with such mutations), Not(Lapatinib and neratinib bind to the HER2 kinase domain))\\n--------\\nImplies(Not(I), Not(G))\\nImplies(Not(Patients with ERBB2 V777L may access open clinical trials), Not(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma))\\n--------\\nImplies(G, I)\\nImplies(ERBB2 V777L is an inclusion criterion in clinical trials for breast carcinoma, Patients with ERBB2 V777L may access open clinical trials)\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(Effective in breast cancer patients), Not(An irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(D, F)\\nImplies(An irreversible inhibitor targeted to the HER2 kinase domain, Effective in breast cancer patients)\\n--------\\nImplies(A, C)\\nImplies(Lapatinib and neratinib bind to the HER2 kinase domain, Direct benefit to patients with such mutations)\\n--------\\n'}"
        ]
    }
}